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The gastrointestinal microbiota is a major source of immune stimulation. The interaction between host pattern-recognition
receptors and conserved microbial ligands profoundly influences infection dynamics. Identifying and understanding the nature
of these interactions is a key step towards obtaining a clearer picture of microbial pathogenesis. These interactions underpin a
complex interplay between microbe and host that has far reaching consequences for both. Here, we review the role of pattern
recognition receptors in three prototype diseases aﬀecting the stomach, the small intestine, and large intestine, respectively
(Helicobacter pylori infection, Salmonella infection, and inflammatory bowel disease). Specifically, we review the nature and impact
of pathogen:receptor interactions, their impact upon pathogenesis, and address the relevance of pattern recognition receptors in
the development of therapies for gastrointestinal diseases.
1. Introduction
Microbes play key roles in both health and disease. This
is particularly relevant in the gastrointestinal (GI) tract,
where the high bacterial load (up to 1012 bacteria/ml)
ensures a continual source of immune stimulation. The
gastrointestinal immune system is intricately designed not
only to identify and isolate pathogenic organisms but
also to continue a predominantly symbiotic host-bacterial
relationship that often exists for mutual benefit. The out-
ermost sentinels are the intestinal epithelial cells (IECs)
that line the gut and act as a physical barrier between the
luminal contents and the host immune system. However,
these cells are not passive players and contribute to the
innate immune response by expressing pattern recognition
receptors (PRRs) that can identify and respond to micro-
bial organisms. They also express major histocompatibil-
ity antigens and act as antigen-presenting cells bridging
innate and adaptive immunity. Further specialised antigen
presenting cells include M cells in the epithelial lining
and dendritic cells in the lamina propria. Together, these
contribute key innate and adaptive immune responses [1,
2].
T cells are the major cellular components of the adaptive
response and are located between epithelial cells (intraep-
ithelial lymphocytes) and in the lamina propria. Nomadic
intraepithelial lymphocytes contribute barrier functions and
help maintain intestinal epithelium integrity. Several T cell
subsets (TH1, TH2, and TH17) are present in the lamina
propria resulting in distinct and characteristic cytokine
responses that help prevent systemic spread of pathogens.
Activation of B cells, often within Peyer’s patches in the lam-
ina propria resulting in antibody production and secretory
IgA, for example, has a key role in influencing luminal events.
The commensal gut microbiota paradoxically influence
maturity and the development of this local immune system
[3]. The host in turn develops “tolerance” to this large and
diverse group of bacteria. This relative unresponsiveness is
mediated by another group of cells called T regulatory cells
(Tregs) [4]. The current paradigm of immune tolerance
suggests that commensal bacteria may in fact influence and
promote diﬀerentiation of Tregs resulting in a mechanism
to tolerate foreign antigens of the microbiota [5]. These
areas of research are likely to be crucial in enabling us to
comprehend the molecular mechanisms by which the gut
microbiota conducts and regulates immune homeostasis.
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Table 1: Pattern recognition receptor activating ligands from Salmonella spp. and Helicobacter pylori.
PRR Salmonella spp. ligand Helicobacter pylori ligand
TLR1/2/6 Lipoproteins Membrane protein HpaA
TLR4 Lipopolysaccharide (LPS) Tetra-acylated LPS (poorly immunogenic) Hexa-acylated LPS
TLR5 Flagellin (FliC) Flagellin (very poor stimulator)
TLR9 CpG rich repetitive elements in Salmonella DNA Bacterial nucleic acid
NLRC4 Flagellin (FliC), T3SS protein PrgJ ?
NOD1 Peptidoglycan Peptidoglycan
Table 2: TLR expression within the gastrointestinal tract. (Adapted from Fukata and Abreu 2008 and Gribar et al. 2008) [11, 19].
TLR Stomach Small intestine Large intestine
1 Not detected RNA RNA
2 RNA RNA/protein RNA/protein
3 Not detected RNA/protein RNA/protein
4 RNA/protein RNA/protein RNA/protein
5 RNA/protein RNA/protein RNA/protein
6 Not detected Not detected RNA
7 Not detected Not detected RNA
8 Not detected Not detected RNA
9 RNA/protein RNA/protein RNA
10 Not detected Not detected Absent
11 Not detected Not detected Not detected
As outlined above the interaction of commensal and
pathogenic bacteria with PRRs influences both the imme-
diate and adaptive immune responses. This can aﬀect the
nature of the commensal species and the outcome of
pathogenic infection. In this paper, we will focus on the con-
tribution of PRRs in diseases of three anatomically diverse
sites within the GI tract. Specifically, Helicobacter pylori
and the stomach, Salmonella spp. and the small intestine,
and inflammatory bowel disease and colonic microbiota.
We will discuss the contribution of pathogen:PRR inter-
action to pathogenesis and consider how understanding
PRR:pathogen interplay can aid therapeutic treatment and
development.
PRRs consist of four main receptor families: Toll-like
receptors (TLRs), nucleotide-binding domain leucine-rich
repeat containing receptors (NLRs), RIG-I like receptors
(RLRs), and the C-type lectin family [6]. The membrane
bound TLR and cytosolic NLR family members are par-
ticularly relevant for the three diseases under discussion.
Various molecules act as PRR stimuli in each of these
diseases (Table 1) [6, 7]. Whilst PRRs are known to be found
in immune cells such as macrophages and dendritic cells,
their presence on other cell types, including gastrointestinal
epithelial cells, which are likely to come in to contact with
microorganisms, is less well understood.
Expression of TLRs is nonuniform throughout the gas-
trointestinal tract with expression of TLRs in the oesophagus
having not been documented to date. In the stomach,
expression of TLR2, 4, 5, and 9 has been demonstrated
[8–10] (Table 2). TLR expression in the intestines is more
extensive although under normal physiological conditions,
TLR expression in IECs is downregulated [11].
PRRs respond to evolutionarily conserved ligands
whether derived from friend or foe. The host must retain
the ability to detect and mount an appropriate immune
response to pathogenic bacteria, whilst simultaneously
avoiding inappropriate, or excessive, responses to the com-
mensal microbiota [12]. Many mechanisms are employed
within the GI tract to facilitate successful discrimination.
These include PRR downregulation from the apical epithelial
surface, PRR signaling crosstalk, requirements for multiple
PRR activation, and negative regulation of PRR signaling
(reviewed in [13]). Understanding the role of the PRRs of the
innate immune system in the homeostatic and pathogenic
functioning of the GI system is essential if we are to
successfully manage and treat diseases that already place a
significant burden on the healthcare system.
2. PRRs and Helicobacter pylori
Helicobacter pylori is a ubiquitous, noninvasive Gram-
negative bacterium that colonises the stomach of nearly half
of the world’s population [14]. It is associated with chronic
gastritis, duodenal ulcer, gastric ulcer, gastric adenocarci-
noma, and gastric MALT lymphoma. H. pylori organisms
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reside in the gastric acidic milieu, just below the mucous
layer in close proximity to the gastric epithelium. Infection
outcome is determined by both bacterial pathogenicity
factors and host susceptibility factors [15, 16]. Innate
immune receptors play an integral role in recognition and
subsequent pathogenesis of H. pylori. Infection is established
following adherence of the bacteria to the gastric mucosal
cells. H. pylori has a tropism for gastric mucosal cells
suggesting the presence of receptors that aid in docking
on to the epithelial surface. (Table 1 and Figure 1(a)). Of
the cell surface PRRs, TLR2, 4, and 5 have been studied
most extensively in the context of H. pylori infection. Initial
studies by Backhed et al. showed that TLR2, TLR4, and TLR5
were detected in biopsies taken from patients with H. pylori
infection, but TLR4 was not found in the subset of antral
gastric epithelial cell preparations [17]. The investigators
then challenged TLR4 expressing cells with both cagPAI
positive and negative H. pylori. The former strains elicited
an IL-8 response, whereas the latter did not, suggesting that
response toH. pyloriwas cagPAI dependant and independent
of TLR4. In contrast, a similar study utilising clinical
isolates ofH. pylori showed that cytokine-inducing activity of
H. pylori LPS was mediated by TLR4 [18]. Utilising TLR4−/−
macrophages, these investigators further demonstrated a lack
of response toH. pylori lipopolysaccharide (LPS), confirming
the importance of TLR4. Surprisingly, the cytokine response
to whole H. pylori bacteria was mediated not by TLR4 but
rather by TLR2 [18]. However, subsequent work demon-
strated apical and basolateral expression of TLR4 on gastric
cells in non-inflamed gastric epithelium and also in patients
with H. pylori infection [8, 10]. Confocal microscopy also
showed direct attachment of H. pylori bacteria to the TLR4
receptor at the apical pole [10].
As with all Gram-negative bacteria, LPS is a major
cell surface component of H. pylori. However, H. pylori
(along with a collection of other Gram-negative bacteria, for
example, Y. pestis, P. gingivalis) have evolved mechanisms
to modify the structure of their LPS (in particular the lipid
A component) in diﬀerent environments [20]. Diﬀerent
lipid A structures have diﬀerent binding aﬃnities to TLR4
complex constituents, and this can lead to altered host
recognition. For example, lipid A of Helicobacter pylori in
comparison to that of Salmonella spp., contains a major
monophosphorylated tetra-acylated lipid A species which is
not thought to bind eﬃciently to the TLR4/MD-2 receptor
complex due to the lack of a phosphate group in the lipid
A anchor [21]. This loss of one or both phosphate groups
from the lipid A anchor is seen in a number of pathogenic
organisms. H. pylori tetra-acylated LPS has poor activity
against TLR4. However, clinical H. pylori isolates have been
shown to possess the less abundant hexa-acylated form
and consequently are much more eﬀective at activating the
TLR4/MD-2 receptor complex. Diﬀerential LPS expression
seen between diﬀerent H. pylori strains could explain the
conflicting evidence regarding recognition of H. pylori LPS
by TLR4.
TLR5 and TLR9 have also been identified in non-
inflamed gastric epithelium and in H. pylori-associated
chronic gastritis. The localization of TLR5 and TLR9 was
found to be exclusively basolateral in H. pylori-associated
chronic gastritis [10], suggesting that these two TLRs may
not be essential forH. pylori recognition [2]. This was further
confirmed by demonstration that aflagellated H. pylori
mutants still induced IL-8 production [22]. TLR5 does
interact with H. pylori flagellin, but the interaction induces
only weak receptor activation [23]. This was confirmed by an
elegant study in which TLR5 responsive motifs in Salmonella
flagellin were replaced with the equivalent regions from
H. pylori. This rendered the flagellin inactive against TLR5
[24]. Evasion of TLR5-mediated bacterial detection may be
a major mechanism for immune escape and persistence by
H. pylori.
The involvement of TLR9 in Helicobacter pathogenesis
has not been extensively studied. A recent murine study, by
Rad et al. [25], identified the potential of H. pylori DNA to
act as a TLR9 ligand. This work also reported the induction
of proinflammatory cytokines and type I IFN-stimulated
genes in murine dendritic cells by H. pylori RNA in a
TLR- and RIG-I-dependent mechanism, respectively. This
study utilised direct transfection of H. pylori nucleic acid to
activate the relevant receptors. Whilst dendritic cells appear
capable of eﬃciently internalising live H. pylori, the precise
mechanisms by which ligands are presented to intracellular
PRRs remain to be clarified.
The ability of other immune cell types to respond to
H. pylori has also been documented. Natural killer (NK)
cells respond to H. pylori-specific membrane-bound protein
HpaA to produce interferon gamma (IFNγ) following activa-
tion of either TLR2:TLR1 or TLR2:TLR6 heterodimers [26].
The exact relevance of NK cell activation by H. pylori in
infection is not known. However, NK cells may gain access
to the H. pylori antigens in the mucosa as a result of leaky
intercellular tight junctions. Given that gastric cancer is one
of the known sequelae of H. pylori chronic gastritis one
can speculate that H. pylori-mediated NK cell activation and
subsequent IFNγ production could contribute to tumour
immunosurveillance.
The ability of H. pylori to activate intracellular PRRs also
extends to the cytoplasmic NLR family. Current evidence
suggests that cytoplasmic PRRs are exposed to H. pylori
either following endocytosis or via the action of the
cagPAI encoded type IV secretion system (Figure 1(a)). This
system allows bacterial proteins such as CagA as well as
peptidoglycan fragments to be injected into the epithelial
cell cytosol. An alternative method for peptidoglycan entry
into cells has recently been proposed by Kaparakis et al.
[27]. They suggest that bacterial outer membrane vesicles,
containing peptidoglycan fragments, associate and fuse with
lipid rafts on the host cells and divest their contents into
the cytoplasm. It may well be that both these mechanisms
are employed during infection. Once in the cell, H. pylori
peptidoglycan is recognised by the NLR protein NOD1 [28].
Activation of NOD1 leads to receptor oligomerisation and
the recruitment of the cellular kinase receptor interacting
protein 2 (RIP2). RIP2 is activated via induced proximity and
subsequently targets IKK (inhibitor of nuclear factor kappa
B (NF-κB) kinase) γ for degradation, allowing IKKα and
IKKβ to phosphorylate IκB and initiate NF-κB release and
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Figure 1: The interaction of Helicobacter pylori and Salmonella spp. with pattern recognition receptors. Schematic representations of the
PRRs, activating ligands, and simplified activation pathways for innate immune signaling for (a) Helicobacter pylori and (b) Salmonella
enterica serovar Typhimurium. Both pathogens activate multiple PRRs found on cellular membranes and in the cytoplasm. Together,
this instigates a complex interplay of signaling crosstalk that influences the host response to the pathogen and results in induction of a
proinflammatory immune response. In the case of Salmonella spp., activation of caspase-1 via NLRC4 ultimately leads to cell death via
pyroptosis. H. pylori electron micrograph image provided courtesy of Professor Dave Kelly, University of Sheﬃeld, UK. Electron micrograph
image of Salmonella enterica serovar Typhimurium provided courtesy of Professor Sangwei Lu, UC Berkeley.
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nuclear translocation. The use of the adaptor CARD (caspase
activation and recruitment domain) 9, rather than RIP2,
activates the stress kinase pathway. Both pathways initiate a
strong proinflammatory immune response which includes
the production of antimicrobial β-defensins, thereby helping
to mediate bacterial killing [29, 30]. NOD2 signalling follows
a very similar pathway to NOD1.
The presence of functional polymorphisms in genes of
the innate immune system can aﬀect pathogenesis and the
magnitude and direction of the host’s response to infection.
They may also impact on the eﬀectiveness of subsequent
therapeutic strategies [31]. Hundreds of single nucleotide
polymorphisms (SNPs) have been identified in PRRs, but the
functional consequences of only a few have been defined.
The TLR4 polymorphism (TLR4 Asp299Gly) decreases
responsiveness to LPS [32] and has a positive correlation
with susceptibility to several infectious diseases including
H. pylori-induced gastric cancer [33]. Other functional PRR
polymorphisms are also associated with H. pylori-induced
disease: the−1237T/C promoter polymorphism in TLR9, the
−159C/T promoter polymorphism in CD14 (a component
of the TLR4 receptor complex), the TLR2 −196 to 174
deletion promoter polymorphism, and the Glu266Lys NOD1
polymorphism have all been associated with increased risk of
H. pylori attributable disease although this risk is not always
present at all disease stages [34–37].
In conclusion, it is quite evident that the innate immune
system and its wide array of PRRs play a significant role
in recognising H. pylori and triggering antimicrobial host
defense responses. Unlike other Gram-negative bacilli such as
Salmonella spp., the immune response against H. pylori LPS
and flagellin is not as robust and is less defined. This may
well be a result of immune escape mechanisms employed
by the bacteria to aid persistence. Better understanding of
these pathogenic mechanisms will help in targeting PRRs
to develop new therapeutic strategies against H. pylori and
other bacterial pathogens.
3. The Role of PRRs in Salmonella spp.
Pathogenesis
Salmonella spp. are versatile enteric pathogens that employ
multiple virulence determinants to survive within the host
and contribute to pathogenesis. These include Salmonella
pathogenicity island (SPI)-1 and SPI-2-encoded type III
secretion systems (T3SS) and bacterial factors such as LPS
and flagellin. Interaction with the host is a critical element
in S. Typhimurium pathogenesis influencing progression and
outcome of infection. Uptake into epithelial cells early in
infection, or subsequent entry intomacrophages, contributes
to PRR stimulation and plays an important role in balancing
host:pathogen interplay. The key Salmonella ligands and
responsive PRRs are outlined in Table 1 and Figure 1(b).
TLR2 and TLR9 both contribute to detection of
Salmonella and control of pathogenesis. TLR2 contributes
more significantly at high, rather than low, bacterial loads
[38, 39]. TLR9, in turn, is activated by CpG-rich repetitive
DNA elements in the bacterial genome and initiates a strong
interferon-α response [40]. The major TLRs involved in
interaction with Salmonella are, however, TLR4 and TLR5.
These respond to LPS and flagellin, respectively. Mice defec-
tive in TLR4 show an impaired response to S. Typhimurium
infection [39]. Purified LPS from Salmonella induces high
levels of tumour necrosis factor (TNF)-α and nitric oxide in
a manner very similar to direct infection of macrophages.
Activated macrophages also upregulate mitogen-associated
protein kinase JNK and p38 though this appears to be
TLR4 independent [41]. The use of TLR adaptor proteins
is influenced by the bacterial load of Salmonella infection.
For instance, the control of bacterial growth during murine
infection is critically regulated by TLR4 andMyD88 (myeloid
diﬀerentiation factor 88), and not Mal (MyD88 adaptor
like protein) or TRIF (Toll interleukin-1 receptor containing
adaptor inducing IFN-β). TRIF is, however, important for
bacterial killing very early during infection [38, 39]. Mal is
also essential for a full interleukin (IL)-6 response at low,
but not high multiplicity of infection [42]. The variation in
activation threshold and sensitivity for the diﬀerent TLRs to
Salmonella spp. presumably helps regulate the host response,
whilst maintaining the ability to respond rapidly to the
high threat associated with a large bacterial load. One could
postulate that a similar mechanism may contribute to the
discrimination between commensal and pathogenic bacteria
and the maintenance of homeostasis. What is certainly true is
that the cellular response to the detection of Salmonella plays
an important role in the progression and manifestation of
immunopathology.
Salmonella flagellin can interact with TLR5 on the baso-
lateral surface of intestinal cells and also on dendritic cells
in the lamina propria. This interaction involves conserved
regions of FliC [24]. This activation could conceivably
involve direct bacterial contact; however, Salmonella spp.
actively secrete components of the flagella, such as FliC,
via the SPI1 T3SS (Figure 1(b)). These components can
activate TLR5 independently of direct bacterial contact. The
importance of this interaction has been highlighted through
studies with aflagellated bacteria investigating Salmonella-
mediated gastroenteritis and typhoid fever [43, 44]. Loss of
flagella correlated with a reduction in the initial inflamma-
tory response to infection followed by a subsequent increase
in bacterial load, enhanced inflammation, and greater disease
severity. It would therefore seem that, just like TLR4, TLR5
is a key mediator in the interactions between host and
Salmonella spp. and is vital in regulating disease burden and
bacterial replication.
Flagellin subunits are also delivered directly to the
cytoplasm by the SPI1 T3SS, where they activate the intra-
cellular receptor NLRC4 (also known as IPAF) in a TLR5-
independent manner [45, 46]. This results in the formation
of an inflammasome and the recruitment and processing
of procaspase-1. Active caspase-1, subsequently, cleaves pro-
interleukin 1β and 18 into active proinflammatory cytokines,
which are secreted from the cell. Caspase-1 activation can
also lead to cell death via pyroptosis [47]. NLRC4 can also
be directly activated by the T3SS component PrgJ [48]. The
interaction between Salmonella spp. and NLRC4 is complex.
Expression of bacterial stimuli is temporal and, consequently,
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aﬀects the likelihood of detection and immune clearance.
Attenuation of flagellin and PrgJ expression could be viewed
as an immune evasion strategy comparable with LPS vari-
ation in H. pylori. It is conceivable that NLRC4 activation
contributes to bacterial pathogenesis as canines, which
appear to be inherently resistant to Salmonella-mediated
pathology, do not possess a fully functional NLRC4 protein.
In addition to the NLRC4 inflammasome, Salmonella
also activates caspase-1 via the NLRP3 inflammasome [49].
Furthermore, peptidoglycan from Salmonella spp. is recog-
nized by NOD1 [28, 50]. NOD1 activation has been shown to
be important in dendritic cells in the lamina propria [50]. It
is clear that the dynamics of PRR:Salmonella interaction are
complex and contribute to the establishment, progression,
and clearance, or otherwise, of infection. As with H. pylori,
host genetics can influence the progression of Salmonella
mediated disease. As yet, there are no published connections
between PRR SNPs and disease outcome. However, recently
a genome-wide screen linked SNPs in the immune regula-
tor CARD8 with susceptibility to Salmonella-mediated cell
death [51].
4. Pathogenesis of Inflammatory Bowel Disease:
Interaction of PRRs with Gut Microbiota
Inflammatory bowel disease (IBD) comprising of ulcerative
colitis (UC) and Crohn’s disease (CD) is an idiopathic disease
characterized by chronic inflammation of the gut. Over
the years, several pathogenic theories have been postulated,
ranging from psychosomatic to autoimmunity to allergic
to genetic predisposition. Our understanding has evolved,
and the current consensus of the aetiopathogenesis of these
conditions involves one of four components: global changes
in the environment, eﬀect of genetic variations, aberrations
of innate and adaptive immune responses in handling
microbiota, and changes in the luminal microbiota [52].
The colonic epithelium lies in close proximity to a diverse
luminal microbiota. This microbial ecosystem is critical
in the maintenance of normal homeostasis through their
symbiotic contribution to diverse processes that include
digestion, absorption, the supply of essential nutrients,
and protection from pathogenic microorganisms [53]. In
patients with IBD, this delicate balance is disturbed as a
result of host immune defects in recognition or impaired
clearance of pathogenic microbes [54]. PRRs are essential
in distinguishing “friend from foe” in this very complex
interaction and hold the key to understanding how genetic
factors lead to an abnormal immune environment, wherein
normal commensal organisms can lead to pathological
chronic inflammation (Figure 2).
The normal colonic epithelium constitutively expresses
TLR3 and TLR5, whereas TLR2 and TLR4 are barely
detectable [55]. Distinct changes in TLR expression have
been documented in IBD. TLR4 is found to be upregulated
in both UC and CD, whereas the levels of TLR2 and
TLR5 remain unchanged [56]. In IBD, increased TLR2
and TLR4 expression has been documented in the resident
macrophages of the lamina propria [57]. These changes
can explain some of the abnormal response to the resident
gut microbiota. However, it is diﬃcult to elucidate whether
the change in TLR expression initiates disease or is an
epiphenomenon resulting from proinflammatory cytokine
release. For example, both TNFα and IFNγ have been
shown to increase expression of TLR4 and MD2 and hence
responsiveness to LPS [58].
The key role of TLR in the pathogenesis of IBD has been
elegantly demonstrated in murine models of colitis. TLR4
and MyD88 knockout mice had distinctly less inflammation
after chemical induction of colitis with dextran-sodium
sulphate (DSS) as opposed to wild-type mice but grew
Gram-negative bacilli more frequently from their mesenteric
nodes [59]. This highlights the critical role of TLR4 as a
first line of defense against potential bacterial pathogens.
Impairment of TLR4 function permits bacterial invasion and
persistence and could lead to the characteristic inflammation
of IBD. The importance of TLR5 in intestinal homeostasis
has been eﬀectively demonstrated using microbiota transfer
from knockout mice [60]. In this work, loss of TLR5
was associated with development of metabolic syndrome.
Interestingly, TLR5 activation by flagellin has been shown
not to cause inflammation in normal animals but to enhance
the changes associated with DSS colitis [61].
One can postulate that multiple “hits” by diﬀerent bacte-
rial species may exacerbate and perpetuate the inflammatory
cascade through the mediation of TLRs. Intriguingly, the
administration of CpG oligodeoxynucleotides, the ligand
for TLR9, did not exacerbate inflammation but instead
dampened the inflammation associated with experimental
colitis [62]. The activation of an inflammatory receptor
to dampen the immune response seems counterintuitive.
It does, however, highlight the complex interplay between
PRR initiated signaling cascades and reinforces the need for
further research to improve our understanding of how these
receptors function in clinical settings. After all, modulation
of PRRs, such as the activation of TLR9, could be the basis
for probiotic use in the treatment of IBD. On the other hand,
the bacterial composition has also been found to distinctly
change in models of experimental colitis, which in itself may
alter pathogenesis and the response to therapy. Either TLR2,
TLR4, and TLR5 ligands or the PAMP profile was distinctly
diﬀerent in faecal and intestinal biopsy samples from rats
with DSS colitis as opposed to controls [63]. It remains to be
seen whether this “dysbiosis” is the initiating or a secondary
phenomenon in the pathogenesis of IBD (Figure 2).
The evidence that TLRs play a role in IBD has also been
extrapolated from the study of genetic polymorphisms in
human subjects. Two common functional polymorphisms of
TLR4 (TLR4 Asp299Gly and Thr399Ile) have been associated
with both UC and CD in Caucasian populations [64–66].
Polymorphisms in TLR1 and TLR2 genes (TLR1 R80T
and TLR2 R753G) have been associated with pancolitis in
UC patients [67]. The association of CD with the TLR9
promoter polymorphism (TLR9-1237) discussed previously
due to its significance in the context of H. pylori infection,
which is associated with increased NF-κB-binding aﬃnity,
further confirms the role of bacterial DNA sensing in the
pathogenesis of IBD [36, 68].
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Figure 2: The interaction of colonic microbiota and pattern recognition receptors in normal colonic epithelium and in the epithelium of
inflammatory bowel disease. The schematic representation summarizes the key abnormalities at the level of the intestinal lumen, surface
PRRs, and intracellular PRRs in inflammatory bowel disease and compares and contrasts them with normal homeostatic interactions.
The strongest genetic associations for IBD have, how-
ever, been reported for the NLR family member NOD2.
Three polymorphisms have been definitively associated with
increased susceptibility to CD: Arg702Trp, Gly908Arg, and
leu1007fsinsC (a frame-shift mutation that truncates the
carboxy terminal 33 amino acids) [69–71]. Polymorphic
NOD2 proteins are unable to respond to bacterial muramyl
dipeptide (MDP) leading to ineﬀective downstream signal-
ing of NF-κB [72]. This allows infection and translocation
of enteric bacteria to the lamina propria. NOD2 poly-
morphisms also result in alterations in cytokine expression
following exposure of peripheral blood mononuclear cells
to MDP [73, 74]. This may explain some of the alteration
in cytokine profile typically seen in CD. A decrease in
the protective, anti-inflammatory Th-2 cytokine IL-10 has
been documented in NOD2 mutants further adding to our
understanding of the functional abnormalities characteristic
of CD [75]. Counterintuitively, given the potential involve-
ment of dysfunctional NOD2 SNPs, CD is associated with
increased NF-κB signaling. Chronic stimulation of NOD2
may, however, act to tolerise cells against bacterial stimula-
tion [76]. Hence, in CD patients with dysfunctional NOD2
this restraint is removed and the inflammatory response
from other PRRs increases. Additionally, NOD2 has been
implicated in regulation of the cellular process autophagy
through potential interaction with ATG16L1 (autophagy-
related protein 16-l isoform 1) [77, 78]. ATG16L1 has also
been identified as a CD susceptibility gene [79]. The NOD2
CD-associated SNPs appear defective in the initiation of
autophagy, which also functions as an antibacterial defense,
and it may be that this is another facet to the role of NOD2
in the pathophysiology of CD.
Despite the fact that nearly 100 independent genetic
loci have been identified as potential risk factors for the
development of IBD, there are still a large proportion of
cases where these defects have not been identified [80].
These could represent lacunae in our current knowledge
but could also underlie the importance of the resident gut
microbiome that may well be the “environmental factor”
that influences and directs the inflammatory response. PRRs
form an intrinsically critical factor in the interface between
luminal microbiota and the adaptive immune system and
can be useful targets in ameliorating the chronic aberrant
immune response in IBD.
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5. Therapeutic Implications of PRRs for
Gastrointestinal Disease
The intricate involvement of PRRs in immune inflammatory
pathways makes PRRs attractive targets for the develop-
ment of therapeutic strategies. To date, most eﬀorts have
centered on TLRs. Therapeutic approaches to GI tract
diseases are inherently complex. The vast bacterial diversity
of resident gut microbiota and the continual exposure to
high and variable concentrations of PRR ligands results
in continual stimulation from commensal and pathogenic
organisms. Consequently, it is diﬃcult to design therapeutic
interventions that would specifically target pathogenic PRR
responses. One must also consider how the resident micro-
biota may respond to therapies that could potentially disrupt
its homeostatic balance.
TLR therapeutic approaches under development include
the use of both agonists and antagonists. For example, TLR9
agonists are undergoing Phase I/II trials for colorectal cancer
with the hope of optimising drug-induced inflammatory
responses for optimal clinical benefit [81]. In animal models
of colitis, the administration of CpG ameliorated disease
activity, probably mediated by the TLR9 receptor [12]. One
can speculate in the context of colorectal cancer that the
unwanted inflammatory activity is of microbial origin [82].
TLR antagonists in contrast are structural analogues of
agonists which aim to dampen signalling. Currently, TLR4
antagonists are at clinical trial phase for the treatment of
sepsis, with TLR7 and 9 antagonists under development in
lupus [81]. TLR4 antagonists look to inhibit LPS recognition
and are, therefore, a potentially suitable strategy for GI tract
infections. However, to date, this has not been evaluated, and
its usefulness is likely to vary for diﬀerent Gram-negative
stimuli.
Alternative strategies towards microbially induced GI
tract infections include altering the microbial compo-
nent or targeting specific inflammatory pathways down-
stream of specific PRRs. With the understanding that
gut homeostasis requires the interaction of an eﬀective
microbial/epithelial/immune circuit, with each component
communicating with each other, therapeutic strategies are
being developed which aim to restore defective aspects of
the triad. Inhibition of eﬀector T cells through the use of
antibodies targeted against TNF-α is already proving eﬀective
in Crohn’s disease [83]. Small molecular inhibitors of IKK
have also been developed to specifically target the NF-κB
pathway. Other approaches include alteration of the GI
bacterial cohort through antibiotic therapy or probiotics and
genetically engineered microorganisms that inhibit immune
or inflammatory responses.
6. Conclusion
Without doubt, understanding the interplay between host
genetic factors, specifically pertaining to PRRs, and bac-
terial pathogenic mechanisms is crucial. This will be the
cornerstone not only for a better understanding of bacterial
pathogenesis, but also for drug development in the future.
The importance of SNPs upon the outcome of these
interactions is crucial to therapeutic developments and will
play an important role in the development of personalized
medicine.
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